WO2008046140A1 - Improved treatment for benign prostatic hyperplasia - Google Patents

Improved treatment for benign prostatic hyperplasia Download PDF

Info

Publication number
WO2008046140A1
WO2008046140A1 PCT/AU2007/001572 AU2007001572W WO2008046140A1 WO 2008046140 A1 WO2008046140 A1 WO 2008046140A1 AU 2007001572 W AU2007001572 W AU 2007001572W WO 2008046140 A1 WO2008046140 A1 WO 2008046140A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsicum
broccoli
composition
capsicum plants
benign prostatic
Prior art date
Application number
PCT/AU2007/001572
Other languages
French (fr)
Inventor
David Archibald
Original Assignee
Summa Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006905763A external-priority patent/AU2006905763A0/en
Application filed by Summa Development Limited filed Critical Summa Development Limited
Priority to US12/446,007 priority Critical patent/US20100204319A1/en
Priority to AU2007312941A priority patent/AU2007312941A1/en
Priority to EP07815377A priority patent/EP2083840A4/en
Publication of WO2008046140A1 publication Critical patent/WO2008046140A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Definitions

  • the present invention relates to a method and substance useful for improved bladder function-
  • the present invention is directed towards a method and substance for treatment of benign prostatic hyperplasia (BPH)
  • Benign prostatic hyperplasia is one of the most common benign neoplasms in men and is a result of the prostate increasing in size, which in turn exerts pressure on the urethra.
  • BSA One of the most common symptoms of BSA is an incomplete emptying of the bladder which will usually result in an increase in the frequency of urination. Such symptoms include intermittent urine flow, terminal dribbling, lack of ability to control urine flow, nocturia, and effort required to begin urine flow.
  • Finasteride is an adrenergic blocker that inhibits 5- ⁇ -reductase, which can lead to a reduction in size of the prostate over time, although this is usually measured in months and is not a fast acting medication.
  • Normal urine flow is 25ml/sec
  • Finasteride typically raises peak urine flow from 10 ml/sec to 13 ml/sec over some 3 months.
  • a method of treatment for bladder outlet obstruction in a mammal which includes administering to the mammal a therapeutically effective amount of a combination of Capsicum plants and aqueous extract from cruciferous vegetables.
  • the bladder outlet obstruction is caused by benign prostatic hyperplasia.
  • the combination is a synergistic combination.
  • the cruciferous, vegetable is broccoli.
  • the broccoli contains sulforaphane.
  • the ratio of broccoli extract to Capsicum plants is between 10:1 and 100:1 w/w.
  • the ratio of broccoli extract to Capsicum plants is 25:1.
  • capsicum plants are derived from the Capsicum annum species.
  • the finely powdered fruits of the capsicum plants are used.
  • the fruits contain Capsicum vanillo ⁇ ds.
  • the vanilloids are selected from the group consisting of capsaicin and vanillylamine.
  • a further aspect of the invention resides in a composition for treating bladder outlet obst r uction in a mammal, wherein the composition includes a therapeutically effective amount of a synergistic combination of Capsicum plants and an aqueous extract of cruciferous vegetables.
  • the treatment is applicable to a bladder outlet obstruction which is the result of benign prostatic hyperplasia.
  • the cruciferous vegetable is broccoli.
  • the broccoli contains sulforaphane.
  • the ratio of broccoli extract to Capsicum plants is between 10:1 and 100:1 w/w.
  • the ratio of broccoli extract to Capsicum plants is 25:1.
  • capsicum plants are derived from the Capsicum annum species.
  • the finely powdered fruits of the capsicum plants are used.
  • the fruits contain Capsicum vanilloids.
  • the vanilloids are selected from the group consisting of capsaicin and vanillylamine.
  • Lyophilisec broccoli sprouts were obtained from dark grown organic broccoli seeds that had germinated at 25°C and were 3 days old, freeze dried and ground to ⁇ powder. In another instance (Finely ground and sieved sprouts or a commercial preparation of sprouts were cold water extracted overnight and subsequently lyophilized).
  • Capsicum annum fruits of different varieties were then Tiixed with the lyophilized broccoli extract in various ratios ranging from 10:1 to 100:1 w/w, broccoli extract: capsicum plant.
  • the embodiment used a 25:1 ratio w/w broccoli powder: capsicum plant
  • Subject experienced increased urine flow after 5 days, with nocturia being reduced from 5 times per night down to once or twice.
  • PSA prostate specific antigen
  • Finasteride may take approximately 3 months to raise urine flow from 10 ml/sec to 13 ml/sec. Contrast this with the present invention in which it has been observed that urine flow has similar effects in 1-3 days, a significant increase in efficacy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention describes a method and composition for t treatment for bladder outlet obstruction, particularly benign prostatic hyperplasia (BPH). which includes administering to the mammal a therapeutically effective amount of a synergistic combination of Capsicum plants and aqueous extract from cruciferous vegetables.

Description

IMPROVED TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA
FIELD OF THE INVENTION
The present invention relates to a method and substance useful for improved bladder function-
More specifically, the present invention is directed towards a method and substance for treatment of benign prostatic hyperplasia (BPH)
DESCRIPTION OF THE PRIOR ART
In this specification, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date: part of common general knowledge, or known to be relevant to an attempt to solve any problem with which this specification is concerned.
Benign prostatic hyperplasia (BPH) is one of the most common benign neoplasms in men and is a result of the prostate increasing in size, which in turn exerts pressure on the urethra.
The incidence of BPH increases with age, with approximately 90% of males having histologically identifiable symptoms at age 85.
One of the most common symptoms of BSA is an incomplete emptying of the bladder which will usually result in an increase in the frequency of urination. Such symptoms include intermittent urine flow, terminal dribbling, lack of ability to control urine flow, nocturia, and effort required to begin urine flow.
Currently there exists a number of treatments, both medical and surgical, aimed at increasing the peak flow of urine in sufferers. Such treatments include transurethral resection of the prostate (TURP), transurethral incision of the prostate (TJIP), balloon dilation. Finasteride therapy, Alpha blocker therapy or open prostatectomy. Of the above medical treatments Finasteride is one of the most commonly prescribed medications.
Finasteride is an adrenergic blocker that inhibits 5-α-reductase, which can lead to a reduction in size of the prostate over time, although this is usually measured in months and is not a fast acting medication. Normal urine flow is 25ml/sec, Finasteride typically raises peak urine flow from 10 ml/sec to 13 ml/sec over some 3 months.
OBJECT OF THE INVENTION
It is an object of the present invention to provide a method decreasing the size of an enlarged prostate in a mammal.
It is yet a further object of the invention to provide a method of treatment of bladder outlet obstruction.
Λ/lore specifically, it is an object of the present invention to provide a synergistic combination of sulforaphane and capsaicin for the treatment of bladder outlet obstruction in mammals.
It is yet a further object of the present invention to provide a pharmaceutical preparation including a synergistic combination of sulforaphane and capsaicin for the treatment of bladder outlet obstruction in mammals
More spec fically, wherein the cause of the bladder outlet obstruction is benign prostatic hyperplasia.
It is an object of the present invention to overcome, or at least substantially ameliorate the disadvantages and shortcomings of the prior art.
Other objects and advantages of the present invention will become apparent from the following description, taking in connection with the accompanying drawings, wherein, by way of illustration and example, an embodiment of the present invention is disclosed.
SUMMARY OF THE INVENTION According to the present invention, although this should not be seen as limiting the invention in any way, there is provided a method of treatment for bladder outlet obstruction in a mammal, which includes administering to the mammal a therapeutically effective amount of a combination of Capsicum plants and aqueous extract from cruciferous vegetables.
tn preference, the bladder outlet obstruction is caused by benign prostatic hyperplasia.
In preference, the combination is a synergistic combination.
In preference, the cruciferous, vegetable is broccoli.
In preference, the broccoli contains sulforaphane.
In preference, the ratio of broccoli extract to Capsicum plants is between 10:1 and 100:1 w/w.
In preference, the ratio of broccoli extract to Capsicum plants is 25:1.
In preference, the capsicum plants are derived from the Capsicum annum species.
fn preference, the finely powdered fruits of the capsicum plants are used.
In preference, the fruits contain Capsicum vanilloϊds.
In preference, the vanilloids are selected from the group consisting of capsaicin and vanillylamine.
A further aspect of the invention resides in a composition for treating bladder outlet obstruction in a mammal, wherein the composition includes a therapeutically effective amount of a synergistic combination of Capsicum plants and an aqueous extract of cruciferous vegetables.
In preference the treatment is applicable to a bladder outlet obstruction which is the result of benign prostatic hyperplasia. In preference, the cruciferous vegetable is broccoli.
In preference, the broccoli contains sulforaphane.
In preference, the ratio of broccoli extract to Capsicum plants is between 10:1 and 100:1 w/w.
In preference, the ratio of broccoli extract to Capsicum plants is 25:1.
In preference, the capsicum plants are derived from the Capsicum annum species.
In preference, the finely powdered fruits of the capsicum plants are used.
In preference, the fruits contain Capsicum vanilloids.
In preference, the vanilloids are selected from the group consisting of capsaicin and vanillylamine.
DETAILED DESCRIPTION OF THE INVENTION
Lyophilisec broccoli sprouts were obtained from dark grown organic broccoli seeds that had germinated at 25°C and were 3 days old, freeze dried and ground to β powder. In another instance (Finely ground and sieved sprouts or a commercial preparation of sprouts were cold water extracted overnight and subsequently lyophilized).
Finely powdered Capsicum annum fruits of different varieties (pepper powders were then Tiixed with the lyophilized broccoli extract in various ratios ranging from 10:1 to 100:1 w/w, broccoli extract: capsicum plant. The embodiment used a 25:1 ratio w/w broccoli powder: capsicum plant
Assays of the broccoli powder shows that the percentage of sulforaphane is 0.1% although more recent production has now taken this value up to 1.9%.
Several early stage studies were conducted in which subjects suffering from bladder outlet obstruction as a result of benign prostatic hyperplasia were treated by swallowing capsules with a synergistic combination of broccoli powder ard finely powdered Capsicum annum fruits as earlier specifically described.
Subject 1
After taking the combination for 3 days the subject's peak urine flow increased dramatically.
Subject 2
Subject experienced increased urine flow after 5 days, with nocturia being reduced from 5 times per night down to once or twice.
Subject 3
Experienced increased urine flow rate after only 2 days. PSA (prostate specific antigen) levels fell by 18%
Subject 4 .
Increased peak urine flow and nocturia down from 3-4 times per night to once or twice.
Subject 5
Dramatic ir crease in peak urine flow after 24 hours of beginning treatment.
Prior to treatment patient showed sighs of elevating levels of prostate specific antigen (PSA). After starling the treatment with combination of broccoli powder and finely powdered Capsicum annum fruits a dramatic decrease in PSA levels were observed. PSA levels halved in 3 months from beginning treatment.
Subject 6
Experienced positive effect on urine flow, incidence of nocturia also dramatically reduced.
Subject 7 PSA levels fell from 15.4 to 11.3 within two months of beginning treatment with the combination of broccoli powder and finely powdered Capsicum annum fruits.
A comparison of Finasteride with the present invention is significant. Finasteride may take approximately 3 months to raise urine flow from 10 ml/sec to 13 ml/sec. Contrast this with the present invention in which it has been observed that urine flow has similar effects in 1-3 days, a significant increase in efficacy.
This then for the first time shows the dramatic effect of the synergistic combination of broccoli powder and finely powdered Capsicum annum fruits on benign prostatic hyperplasia and PSA.
Although the invention has been herein shown and described in what is conceived to be the most practical and preferred embodiment, it is recognized that departures can be made within the scope of the invention, which is not to be limited to the details described herein but it is to be accorded the full scope of the appended claims so as to embrace any and all equivalent compositions and methods.

Claims

1. A method of treatment for bladder outlet obstruction in a mammal, which includes administering to the mammal a therapeutically effective amount of a combinaiion of Capsicum plants and aqueous extract from cruciferous vegetables.
2. The method of claim 1 , wherein the bladder outlet obstruction is caused by benign prostatic hyperplasia.
3. The method of claim 2, wherein the combination is a synergistic combination.
4. The method of claim 3, wherein the cruciferous vegetable is broccoli.
5- The method of claim 4, wherein the broccoli contains sulforaphaπe.
6. The method of claim 5, wherein the ratio of broccoli extract to Capsicum plants is between 10:1 and 100:1 w/w.
7. The method of claim 6, wherein the ratio of broccoli extract to Capsicum plants is 25:1.
8. The method of any one of claims 1-7, wherein the capsicum plants are derived from the Capsicum annum species.
9. The method of claim 8, wherein the finely powdered fruits of the capsicum plants arε used.
10. The method of claim 9, wherein the fruits contain Capsicum vaπilloids.
11. The method of claim 10, wherein the vanilloids are selected from the group consisting of capsaicin and vanillylamine.
12. A composition including a therapeutically effective amount of a synergistic combination of Capsicum plants and an aqueous extract of cruciferous vegetables.
13- The composition of claim 12. wherein the cruciferous vegetable is broccoli.
14. The composition of claim 13, the broccoli contains sulforaphane.
15. The composition of claim 14, the ratio of broccoli extract to Capsicum plants is between 10:1 and 100:1 w/w.
16. The composition of claim 15, the ratio of broccoli extract to Capsicum plants is 25:1.
17. The composition of claim 16, the capsicum plants are derived from the Capsicum annum species.
18. The composftion of claim 17, the finely powdered fruits of the capsicum plants are used.
19. The composition of claim 18, the fruits contain Capsicum vanilloids.
20. The composition of claim 19, the vanilloids are selected from the group consisting of capsaicin and vanilfylamine.
21. A composition including a therapeutically effective amount of a synergistic combination of Capsicum plants and an aqueous extract of cruciferous vegetables when used in the treatment of benign prostatic hyperplasia.
22. A composition for the treatment of benign prostatic hyperplasia, substantially as hereinbefore described.
23. A method of treatment for benign prostatic hyperplasia, substantially as hereinbefore described.
PCT/AU2007/001572 2006-10-17 2007-10-17 Improved treatment for benign prostatic hyperplasia WO2008046140A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/446,007 US20100204319A1 (en) 2006-10-17 2007-10-17 Treatment for benign prostatic hyperplasia
AU2007312941A AU2007312941A1 (en) 2006-10-17 2007-10-17 Improved treatment for benign prostatic hyperplasia
EP07815377A EP2083840A4 (en) 2006-10-17 2007-10-17 Improved treatment for benign prostatic hyperplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006905763 2006-10-17
AU2006905763A AU2006905763A0 (en) 2006-10-17 Improved treatment for benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
WO2008046140A1 true WO2008046140A1 (en) 2008-04-24

Family

ID=39313504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2007/001572 WO2008046140A1 (en) 2006-10-17 2007-10-17 Improved treatment for benign prostatic hyperplasia

Country Status (4)

Country Link
US (1) US20100204319A1 (en)
EP (1) EP2083840A4 (en)
AU (1) AU2007312941A1 (en)
WO (1) WO2008046140A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021125931A1 (en) * 2019-12-19 2021-06-24 Centro De Retina Médica Y Quirúrgica, S.C. Supplement comprising a mixture of capsaicin and sulforaphane as an anti-inflammatory, anti-fibrotic and analgesic coadjuvant for inflammation of the gastric mucosa, gastritis caused by different agents

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056941A1 (en) * 2005-11-15 2007-05-24 Jingcai Cheng The use of isothiocyanates compounds in treating prostatic diseases and skin cancer
CN102659651B (en) * 2012-03-31 2014-04-02 北京化工大学 Preparation method of isothiocyanate compound
TWI533877B (en) 2012-06-27 2016-05-21 景鑫生物科技有限公司 Extract of asplenium nidus linn.
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
IT201900010806A1 (en) * 2019-07-03 2021-01-03 Atlantide S R L COMPOSITION CONTAINING SEQUOIA EXTRACT IN PUMPKIN OIL TO MAINTAIN PROSTATE FUNCTIONALITY
IT201900010800A1 (en) * 2019-07-03 2021-01-03 Atlantide S R L COMPOSITION CONTAINING PRICKLY PEAR EXTRACT IN SERENOA OIL FOR THE MAINTENANCE OF PROSTATE FUNCTIONALITY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
WO2006017904A1 (en) * 2004-08-19 2006-02-23 Purdue Research Foundation Improved anticancer treatment
WO2006053415A1 (en) * 2004-11-18 2006-05-26 Biopharmacopae Design International Inc. Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187811B1 (en) * 1998-10-28 2001-02-13 Lipogenics, Inc. Methods for treating benign prostatic hyperplasia using tocotrienols

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
US20040185122A1 (en) * 1999-03-19 2004-09-23 Pharmacia Corporation Selective COX-2 inhibition from edible plant extracts
US20040052870A1 (en) * 2000-12-15 2004-03-18 Obukowicz Mark G. Selective cox-2 inhibition from edible plant extracts
WO2006017904A1 (en) * 2004-08-19 2006-02-23 Purdue Research Foundation Improved anticancer treatment
WO2006053415A1 (en) * 2004-11-18 2006-05-26 Biopharmacopae Design International Inc. Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHU Y.-F. ET AL.: "Antioxidant and Antiproliferative Activities of Common Vegetables", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 50, no. 23, 2002, pages 6910 - 6916, XP002980140 *
NUTRA INGREDIENTS.COM: "Cruciferous veg, chilli could slow or stop cancer cell growth", 20 April 2005 (2005-04-20), XP008112189, Retrieved from the Internet <URL:http://www.nutraingredients.com/news/printNewsBis.asp?id=59515> *
See also references of EP2083840A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021125931A1 (en) * 2019-12-19 2021-06-24 Centro De Retina Médica Y Quirúrgica, S.C. Supplement comprising a mixture of capsaicin and sulforaphane as an anti-inflammatory, anti-fibrotic and analgesic coadjuvant for inflammation of the gastric mucosa, gastritis caused by different agents

Also Published As

Publication number Publication date
AU2007312941A1 (en) 2008-04-24
US20100204319A1 (en) 2010-08-12
EP2083840A4 (en) 2012-01-25
EP2083840A1 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
US20100204319A1 (en) Treatment for benign prostatic hyperplasia
Owoyele et al. Anti-inflammatory activities of ethanolic extract of Carica papaya leaves
Abbas et al. Long-term outcome of endorectal advancement flap for complex anorectal fistulae
US20070041994A1 (en) Compositions and methods for treating prostate disorders
Crawford Challenges in the management of prostate cancer
US20020090405A1 (en) Components of canola for the treatment of cancer
Cruz-Muñoz et al. Ethanolic extract from Lepidium virginicum L. ameliorates DNBS-induced colitis in rats
AU2012100258A4 (en) Improved treatment for benign prostatic hyperplasia
CN108771661A (en) One plant sterols soft capsule of lycopene
Muhialdin et al. Gastro-Protective and Therapeutic Effect of Punica granatum against Stomach Ulcer Caused by Helicobacter Pylori
Usman et al. Effects of L-arginine and L-citrulline on indomethacin-induced gastric ulceration and gastric pH in male albino rats.
Ambardar et al. A better understanding of traditional uses of Careya arborea Roxb.: Phytochemical and pharmacological review
CN111920908A (en) Pharmaceutical composition for treating peptic ulcer
Avinash et al. Peptic ulcer: a review with emphasis on plants from Cucurbetaceae family with antiulcer potential
KR20180101411A (en) Pharmaceutical composition for the treatment of prostatic hyperplasia
Bharskar Review on phytochemistry and pharmacological aspects of Pedalium murex Linn
WO2004103387A1 (en) The uses of bamboo leaf total flavones for the preparation of medicaments and health foods for preventing and treating for prostate diseases
Namer et al. A randomized double-blind study evaluating Anandron® associated with orchiectomy in stage D prostate cancer
Kondas et al. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia
CN114533779A (en) Thymus extract and its use
Oluwatoyin et al. Study of aqueous leaf extracts of Spondias mombin Linn.(Anacardiaceae) in gastric ulcer models and the possible mechanisms of action
KR101043596B1 (en) Composition for Improving Urologic Function Using Extraction of Bokbunja
Kheirandish et al. Protective effect of trigonella foenum graecum (fenugreek) seed extract on experimental intestinal ischemia/reperfusion injury in rats
Saxena et al. Herbal Drugs in Benign Prostrate Hyperplasia (BPH). A Uurrent Update
KR102167811B1 (en) Herbal Compositions for Treating and Preventing Benign Prostatic Hyperplasia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07815377

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007312941

Country of ref document: AU

Ref document number: 576787

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12446007

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007815377

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007312941

Country of ref document: AU

Date of ref document: 20071017

Kind code of ref document: A